

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number
WO 2004/031229 A2

(51) International Patent Classification⁷: **C07K 14/435**

[GB/GB]; UCL Cruciform Limited, Gower Street, London WC1E 6BT (GB).

(21) International Application Number:

PCT/GB2003/004296

(74) Agent: **HARRISON GODDARD FOOTE**; 31 St. Saviourgate, York YO1 8NQ (GB).

(22) International Filing Date: 3 October 2003 (03.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0223193.4 7 October 2002 (07.10.2002) GB

0306261.9 19 March 2003 (19.03.2003) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicants (*for all designated States except US*): **LUDWIG INSTITUTE FOR CANCER RESEARCH** [CH/CH]; Postfach, CH-8024 Zurich (CH). **GENOME RESEARCH LIMITED** [GB/GB]; The Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA (GB). **UCL Cruciform Limited** [GB/GB]; Gower Street, London WC1E 6BT (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **LU, Xin** [CN/GB]; Ludwig Institute for Cancer Research, Imperial College School of Medicine at St Mary's, Norfolk Place, London W2 1PG (GB). **KUWABARA, Patricia** [US/GB]; Genome Research Limited, The Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA (GB). **SELWOOD, David**

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **POLYPEPTIDE**

(57) Abstract: The invention relates to a polypeptide, or part thereof, which inhibits the apoptotic activity of the tumour suppressor protein p53 and including screening methods to identify agents which interfere with the activity of said polypeptide.

WO 2004/031229 A2

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number
WO 2004/031229 A3

(51) International Patent Classification⁷: C07K 14/47,
A61K 38/16

(21) International Application Number:
PCT/GB2003/004296

(22) International Filing Date: 3 October 2003 (03.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0223193.4 7 October 2002 (07.10.2002) GB
0306261.9 19 March 2003 (19.03.2003) GB

(71) Applicants (for all designated States except US): LUDWIG INSTITUTE FOR CANCER RESEARCH [CH/CH]; Postfach, CH-8024 Zurich (CH). GENOME RESEARCH LIMITED [GB/GB]; The Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA (GB). UCL Cruciform Limited [GB/GB]; Gower Street, London WC1E 6BT (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): J.L. Xin [CN/GB];

Ludwig Institute for Cancer Research, Imperial College School of Medicine at St Mary's, Norfolk Place, London W2 1PG (GB). KUWABARA, Patricia [US/GB]; Genome Research Limited, The Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA (GB). SELWOOD, David [GB/GB]; UCL Cruciform Limited, Gower Street, London WC1E 6BT (GB).

(74) Agent: HARRISON GODDARD FOOTE; 31 St. Saviourgate, York YO1 8NQ (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

[Continued on next page]

(54) Title: P53 BINDING POLYPEPTIDE

1 GCGGCCGCGT CGACCCGGCG TTCAGACGCG GGCAGCTACC GCGGCTCGCT GGGCTCCGCG
61 GGGCCGTCGG GCACITTTGCC TCGCAGCTGG CAGCCCGTCA GCCGCATCCC CATGCCCCCC
121 TCCAGCCCCC AGCCCCCGCG GCGCCCGCGC CAGCGTCCCA TCCCCTCAG CATGATCTTC
181 AAGCTGCAGA AGCCTTTCTG GGAGCAGCGG GCCAGCCCGC CATGCTCCC TGGTCCCCC
241 CTCTTACCC GAGCAGCCCC GCCTAAGCTG CAGCCCCAAC CACAACCACA GCCCAGCCA
301 CAATCACAAC CACAGCCCCA GCTGCCCAA CAGCCCCAGA CCAACCCCA AACCCCTACC
361 CCAGCTCCC ACATCCGCAT CCCCACAGA CATGGCCCC TGTGAACGAA GGACCCCCA
421 AACCCCCAC CGAGCTGGAG CCTGAGCCGG AGATAGAGGG GCTGCTGACA CCACTGCTGG
481 AGGCTGGCGA TGTGGATGAA GGACCTGTA GCAAGGCCCTC TCAGCCCCAC GAGGCTGCAG
541 CCAGCACTGC CACCGGAGGC ACAGTCGGTG CCCGAGCTGG AGGAGGTGGC ACGGGTGTG
601 GCGGAAATTC CCCGGCCCT CAAACGAGG GGCTCCATGG AGCAGGCCCC TGCTGTGGCC
661 CTGCCCCCTA CCCACAAGAA ACAGTACCAG CAGATCATCA GCCGCCCTC CATCTGTCAT
721 GGGGGGGCAG GGCCCGGGGG GCGGAGCCAG AGCTGTCCCC CATCACTAG GATCTGAGG
781 CCAGGGCAGG GCGCCCTGCT CCGTCCCAAC CAGCTCCCAT TCCAGCCGCC GGCCCGCTCC
841 CAGAGCAGCC CACCAGAGCA GCCCAGAGC ATGGAGATGC GCTCTGTGCT GCGGAAAGCG
901 GGCTCCCCGC GCAAGGCCCG CCGCGCGCGC CTCACCCCTC TGGTGTCTCT CCGGACGCG
961 GCGCTGACCG GGGAGCTGGA GGTGGTGCAG CAGGCGGTGA AGGAGATGAA CGACCCGAGC
1021 CAGCCCAACG AGGAGGGCAT CACTGCTTG CACAACGCCA TCTGCGGCGC CAACACTCT
1081 ATCGTGGATT TCCTCATCAC CCGGGTGGC AATGTCAACT CCCCCGACAG CCACGGCTGG
1141 ACACCCCTGC ACTGCGCGGC GTGCTGCAAC GACACAGTCA TGTGATGGC GCTGTGACG
1201 CACGGCGCTG CAATCTTCGC CACCACGCTC AGCAGCGGCG CCACCGCCTT CGAGAAGTGC
1261 GACCCCTTAC GCGAGGGTTA TGCTGACTGC GCCACCTACC TGGCAGAGCT CGAGCAGAGT
1321 ATGGGGCTGA TGAACAGCGG GGCAGGTGAC GCTCTGTGG ACTACAGCGC CGAGTTCGGG
1381 GACGAGCTGT CTTTCCGCGA GGGCGAGTGC GTACCCGTGC TGGGAGGGA CCGGCCGAG
1441 GAGACGACT GGTGGTGGGC CCGCTGCAC GGCCAGGAGG GTACGTGCCC CCGGAAGTAC
1501 TTGCGGCTGT TCCCCAGGGT GAAGCCCTAA AGGAGTAAAG TCTAGCAGGA TAGAAGGAGG
1561 TTTTGAGGC TGACAGAAAC AAGCATTCCT GCCTTCCCTC CAGACCCTC CTTCTGTTT
1621 TTGCTGCCCT TATCTGACCC CCTCACCTG CTGGTGGTGG TCCTTGCCAC CGGTTCCTG
1681 TTCTCTGGA AGTCCAGGGA AGAAGGAGG CCCCAGCCTT AAATTAGTA ATCTGCTTA
1741 GCCTTGGAG GTCTGGGAG GGCTGGAAT CACTGGGAG AGGAAACCAC TTCTTTTGG
1801 CAAATCAGAT CCGCTCCAAA GTGCTCCCA TGCTTACC CATCATACA TCCCAGCA
1861 AGCCAGCCAC CTGCCCCAGC GGGCTGGGA TGGGCCACA CACCACTGGA TATCTCTGG
1921 AGTCACTGCT GACACCATCT TCTCCAGCAG TCTTGGGGTC TGGTGGGAA ACATTGCTT
1981 CTACCAAGAT CCGTGGCCCA CCTCTCCCA ATTAAGTGCC TTACACAGC ACTGGTTAA
2041 TGTATAAAA CAAAATAGAG AAATGTTT AAATGTTTATA AAAAAATAG AGAACTTTC
2101 GCTTATAAAT AAAAGTAGTT TGCACAGAAA TGAAAAA AAAAATAA AAAAAA

(57) Abstract: The invention relates to a polypeptide, or part thereof, which inhibits the apoptotic activity of the tumour suppressor protein p53 and including screening methods to identify agents which interfere with the activity of said polypeptide.

WO 2004/031229 A3



SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
23 September 2004

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 03/04296

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/47 A61K38/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, SEQUENCE SEARCH, WPI Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SAMUELS-LEV YARDENA ET AL: "ASPP proteins specifically stimulate the apoptotic function of p53"</p> <p>MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US,</p> <p>vol. 8, no. 4, October 2001 (2001-10), pages 781-794, XP002202189</p> <p>ISSN: 1097-2765</p> <p>the whole document</p> <p style="text-align: center;">--- -/--</p>	1-54

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the International filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the International filing date but later than the priority date claimed

T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the International search

22 June 2004

Date of mailing of the International search report

30/07/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Young, C

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 03/04296

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>NAUMOVSKI L & CLEARY M L: "The p53-binding protein 53BP2 also interacts with Bcl2 and impedes cell cycle progression at G2/M"</p> <p>MOLECULAR BIOLOGY OF THE CELL, BETHESDA, MD, US,</p> <p>vol. 16, no. 7, 1 July 1996 (1996-07-01), pages 3884-3892, XP002095578</p> <p>ISSN: 1059-1524</p> <p>the whole document</p>	1-54
X	<p>IWABUCHI KUNIYOSHI ET AL: "Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US,</p> <p>vol. 273, no. 40,</p> <p>2 October 1998 (1998-10-02), pages 26061-26068, XP002189291</p> <p>ISSN: 0021-9258</p> <p>the whole document</p>	1-54
X	<p>TAKADA NORIO ET AL: "RelA-associated inhibitor blocks transcription of human immunodeficiency virus type 1 by inhibiting NF-kappaB and Sp1 actions"</p> <p>JOURNAL OF VIROLOGY,</p> <p>vol. 76, no. 16, August 2002 (2002-08), pages 8019-8030, XP002285486</p> <p>ISSN: 0022-538X</p> <p>the whole document</p>	1-54
P,X	<p>BERGAMASCHI DANIELE ET AL: "iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human."</p> <p>NATURE GENETICS,</p> <p>vol. 33, no. 2, February 2003 (2003-02), pages 162-167, XP001180301</p> <p>ISSN: 1061-4036 (ISSN print)</p> <p>the whole document</p>	1-54
T	<p>SLEE ELIZABETH A ET AL: "The ASPP family: Deciding between life and death after DNA damage."</p> <p>TOXICOLOGY LETTERS (SHANNON),</p> <p>vol. 139, no. 2-3,</p> <p>4 April 2003 (2003-04-04), pages 81-87, XP002285487</p> <p>ISSN: 0378-4274</p>	1-54

-/-

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 03/04296

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>DATABASE NCBI 'Online! human RelA associated inhibitor, 20 December 2003 (2003-12-20) TAKANA: "human RelA associated inhibitor blocks transcription of HIV" retrieved from EBI Database accession no. NP_006654 XP002285488 abstract</p>	1-54
T	<p>----- DATABASE NCBI 'Online! 21 November 2003 (2003-11-21) BERGAMASCHI: "iASPP oncoprotein is a key inhibitor of p53" retrieved from EBI Database accession no. NP_505955 XP002285489 abstract</p> <p>-----</p>	1-54